C43 Stock Chart & Stats
€105.00
-€1.00(-1.46%)
At close: 4:00 PM EST
€105.00
-€1.00(-1.46%)
Day’s Range― - ―
52-Week Range€57.50 - €141.00
Previous CloseN/A
Volume64.00
Average Volume (3M)48.00
Market Cap
€1.16B
Enterprise Value€1.58K
Total Cash (Recent Filing)€122.66M
Total Debt (Recent Filing)€4.26M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Mar 24, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding17,543,522
10 Day Avg. Volume20
30 Day Avg. Volume48
Financial Highlights & Ratios
PEG Ratio4.78
Price to Book (P/B)3.74
Price to Sales (P/S)17.21
P/FCF Ratio-113.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€140.64Price Target Upside33.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.11
Revenue Forecast (FY)€115.28M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low debt and substantial equity provide durable financial flexibility. This conservatism supports R&D spending, absorbs operational cash swings, and enables strategic options (partnering, licensing, or selective M&A) without immediate financing pressure over the next 2–6 months.
Partnership/licensing Revenue ModelA business model combining direct product sales with partner-funded development and milestone/royalty streams offers non-dilutive funding and upside tied to partner commercialization. This structure can smooth capital needs and de-risk development versus pure internal commercialization.
Specialized Gastroenterology FocusA clear niche in gastroenterology and endoscopy creates expertise-driven advantages: targeted R&D, specialized sales/clinical channels, and differentiated imaging/therapeutic products that tend to sustain pricing power and partner interest within the specialty market.
Bears Say
Revenue And Profitability VolatilityLarge year-to-year swings undermine visibility into core demand and make planning for steady R&D and commercialization investments difficult. Volatile top-line and margins reduce predictability of recurring earnings and heighten execution risk over the medium term.
Deteriorated Cash Generation In 2025A swing from large positive cash generation to cash burn impairs self-funding capacity and could force reliance on reserves or external funding. Even with a strong balance sheet, negative operating/free cash flow constrains strategic flexibility and increases execution risk.
Unspecified Partner Revenue DetailsKey elements of the partnership/licensing model are unspecified, creating uncertainty about revenue sustainability and concentration risk. Without disclosed terms or contribution breakdowns, future milestone and royalty timing remain unpredictable and may be lumpy.
COSMO Pharmaceuticals N.V. News
C43 FAQ
What was COSMO Pharmaceuticals N.V.’s price range in the past 12 months?
COSMO Pharmaceuticals N.V. lowest stock price was €57.50 and its highest was €141.00 in the past 12 months.
What is COSMO Pharmaceuticals N.V.’s market cap?
COSMO Pharmaceuticals N.V.’s market cap is €1.16B.
When is COSMO Pharmaceuticals N.V.’s upcoming earnings report date?
COSMO Pharmaceuticals N.V.’s upcoming earnings report date is Mar 24, 2027 which is in 244 days.
How were COSMO Pharmaceuticals N.V.’s earnings last quarter?
COSMO Pharmaceuticals N.V. released its earnings results on Jul 23, 2026. The company reported -€0.279 earnings per share for the quarter, missing the consensus estimate of €0 by -€0.279.
Is COSMO Pharmaceuticals N.V. overvalued?
According to Wall Street analysts COSMO Pharmaceuticals N.V.’s price is currently Undervalued.
Does COSMO Pharmaceuticals N.V. pay dividends?
COSMO Pharmaceuticals N.V. does not currently pay dividends.
What is COSMO Pharmaceuticals N.V.’s EPS estimate?
COSMO Pharmaceuticals N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does COSMO Pharmaceuticals N.V. have?
COSMO Pharmaceuticals N.V. has 17,543,522 shares outstanding.
What happened to COSMO Pharmaceuticals N.V.’s price movement after its last earnings report?
COSMO Pharmaceuticals N.V. reported an EPS of -€0.279 in its last earnings report, missing expectations of €0. Following the earnings report the stock price went down -9.483%.
Which hedge fund is a major shareholder of COSMO Pharmaceuticals N.V.?
Currently, no hedge funds are holding shares in DE:C43
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.
C43 Stock 12 Month Forecast
Average Price Target
€140.64
▲(33.94% Upside)